CTI BioPharma (CTIC) Short Interest Ratio & Short Volume → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Free CTIC Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Short InterestStock Analysis CTI BioPharma Short Interest DataCurrent Short Volume11,270,000 sharesPrevious Short Volume8,080,000 sharesChange Vs. Previous Month+39.48%Dollar Volume Sold Short$101.99 millionShort Interest Ratio / Days to Cover2.0Last Record DateMay 31, 2023Outstanding Shares131,880,000 sharesPercentage of Shares Shorted8.55%Today's Trading Volume0 sharesAverage Trading Volume4,496,004 sharesToday's Volume Vs. Average0% Short Selling CTI BioPharma ? Sign up to receive the latest short interest report for CTI BioPharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatCTIC Short Interest Over TimeCTIC Days to Cover Over TimeCTIC Percentage of Float Shorted Over Time Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. CTI BioPharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/31/202311,270,000 shares $101.99 million +39.5%N/A2 $9.05 5/15/20238,080,000 shares $72.15 million -33.6%N/A1.4 $8.93 4/30/202312,170,000 shares $59.15 million -24.2%N/A4 $4.86 4/15/202316,050,000 shares $68.37 million -1.1%N/A5.2 $4.26 3/31/202316,220,000 shares $68.12 million +1.6%N/A5.5 $4.20 3/15/202315,970,000 shares $70.27 million +18.3%N/A5.4 $4.40 Get the Latest News and Ratings for CTIC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for CTI BioPharma and its competitors with MarketBeat's FREE daily newsletter. 2/28/202313,500,000 shares $73.71 million +6.6%N/A4.8 $5.46 2/15/202312,660,000 shares $67.35 million -0.6%N/A4.9 $5.32 1/31/202312,730,000 shares $70.40 million -11.8%N/A4.3 $5.53 1/15/202314,440,000 shares $83.90 million -0.4%N/A4.6 $5.81 12/30/202214,490,000 shares $87.08 million +2.3%N/A4.3 $6.01 12/15/202214,160,000 shares $80.71 million +2.8%N/A4.1 $5.70 11/30/202213,770,000 shares $82.90 million -19.3%N/A3.7 $6.02 11/15/202217,060,000 shares $93.32 million -6.2%N/A4.4 $5.47 10/31/202218,190,000 shares $89.13 million +3.2%N/A4.1 $4.90 10/15/202217,620,000 shares $82.46 million +1.1%N/A4 $4.68 9/30/202217,430,000 shares $101.44 million +2.2%N/A4.2 $5.82 9/15/202217,060,000 shares $105.60 million +8.2%N/A3.7 $6.19 8/31/202215,770,000 shares $99.04 million -12.4%N/A3.3 $6.28 8/15/202218,010,000 shares $102.12 million +10.8%N/A3.5 $5.67 7/31/202216,260,000 shares $106.34 million +4.2%N/A3.4 $6.54 7/15/202215,610,000 shares $102.56 million -12.8%N/A3.4 $6.57 6/30/202217,900,000 shares $106.86 million +20.0%N/A3.8 $5.97 6/15/202214,920,000 shares $86.09 million +14.6%N/A3.3 $5.77 5/31/202213,020,000 shares $70.70 million +41.2%N/A3.4 $5.43 5/15/20229,220,000 shares $38.72 million -1.9%N/A1.5 $4.20 4/30/20229,400,000 shares $48.03 million -7.2%N/A1.7 $5.11 4/15/202210,130,000 shares $45.79 million +1.9%N/A1.9 $4.52 3/31/20229,940,000 shares $46.42 million +19.5%10.8%2 $4.67 3/15/20228,320,000 shares $37.19 million +25.5%9.3%1.8 $4.47 2/28/20226,630,000 shares $12.60 million +4.7%7.4%1.5 $1.90 2/15/20226,330,000 shares $14.75 million +24.6%7.1%3.1 $2.33 1/31/20225,080,000 shares $10.41 million +99.2%5.9%2.4 $2.05 1/15/20222,550,000 shares $5.66 million -14.7%3.0%1.3 $2.22 12/31/20212,990,000 shares $7.42 million -1.6%3.5%1.6 $2.48 12/15/20213,040,000 shares $6.54 million -24.9%3.5%1.7 $2.15 11/30/20214,050,000 shares $9.11 million +1.3%5.1%2.5 $2.25 11/15/20214,000,000 shares $10.44 million -20.3%5.1%4.5 $2.61 10/29/20215,020,000 shares $13.00 million +2.7%6.4%6.3 $2.59 10/15/20214,890,000 shares $13.50 million +4.7%6.3%6.2 $2.76The only AI company you should be looking at (Ad)This is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.Get the stock ticker here >>> CTIC Short Interest - Frequently Asked Questions What is CTI BioPharma's current short interest? Short interest is the volume of CTI BioPharma shares that have been sold short but have not yet been closed out or covered. As of May 31st, traders have sold 11,270,000 shares of CTIC short. Learn More on CTI BioPharma's current short interest. What is a good short interest ratio for CTI BioPharma? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CTIC shares currently have a short interest ratio of 2.0. Learn More on CTI BioPharma's short interest ratio. Is CTI BioPharma's short interest increasing or decreasing? CTI BioPharma saw a increase in short interest during the month of May. As of May 31st, there was short interest totaling 11,270,000 shares, an increase of 39.5% from the previous total of 8,080,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does CTI BioPharma's short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to CTI BioPharma: Spyre Therapeutics, Inc. (10.55%), Collegium Pharmaceutical, Inc. (22.86%), Ironwood Pharmaceuticals, Inc. (13.96%), Belite Bio, Inc (0.12%), Mirum Pharmaceuticals, Inc. (18.21%), Pacira BioSciences, Inc. (7.42%), Ligand Pharmaceuticals Incorporated (4.98%), Verona Pharma plc (7.68%), MannKind Co. (13.21%), AbCellera Biologics Inc. (11.25%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($4.00 billion), Suncor Energy Inc. ($2.98 billion), Charter Communications, Inc. ($2.88 billion), Occidental Petroleum Co. ($2.79 billion), Moderna, Inc. ($2.39 billion), Snowflake Inc. ($2.38 billion), Coinbase Global, Inc. ($2.22 billion), Palantir Technologies Inc. ($2.18 billion), T. Rowe Price Group, Inc. ($2.03 billion), and Verisk Analytics, Inc. ($2.02 billion). View all of the most shorted stocks. What does it mean to sell short CTI BioPharma stock? Short selling CTIC is an investing strategy that aims to generate trading profit from CTI BioPharma as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against CTI BioPharma? A short squeeze for CTI BioPharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CTIC, which in turn drives the price of the stock up even further. How often is CTI BioPharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CTIC, twice per month. The most recent reporting period available is May, 31 2023. More Short Interest Resources from MarketBeat Related Companies: Spyre Therapeutics Short Interest Collegium Pharmaceutical Short Interest Ironwood Pharmaceuticals Short Interest Belite Bio Short Interest Mirum Pharmaceuticals Short Interest Pacira BioSciences Short Interest Ligand Pharmaceuticals Short Interest Verona Pharma Short Interest MannKind Short Interest AbCellera Biologics Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CTIC) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCThe asset beating inflation by 4xColonial MetalsCould Your Accounts Be Frozen?Allegiance GoldThe only AI company you should be looking atBehind the MarketsHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceUrgent Nvidia WarningAltimetry